Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Details : TP-1287 is an investigational oral phosphate prodrug of the CDK9 inhibitor alvocidib. This prevents productive transcription and causes reduction of mRNA in genes (c-MYC and MCL-1) transcription leading in tumor cell apoptosis.
Brand Name : TP-1287
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 10, 2023
Lead Product(s) : Enzomenib,Posaconazole
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The primary objectives of the Phase 1 dose escalation portion of the study are to assess the safety and tolerability of DSP-5336 in relapsed or refractory AML or ALL and to determine the recommended Phase 2 dose (RP2D).
Brand Name : DSP-5336
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 29, 2022
Lead Product(s) : Enzomenib,Posaconazole
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Imeglimin Hydrochloride
Therapeutic Area : Endocrinology
Study Phase : Phase III
Recipient : Metavant Sciences
Deal Size : Not Applicable
Deal Type : Not Applicable
Poxel Provides Update on Metavant Partnership with Imeglimin
Details : Metavant has conducted a strategic review and has decided not to move forward with the development of Imeglimin. Metavant will actively explore options for a potential out-licensing of Imeglimin rights for a period of 60 day.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 20, 2020
Lead Product(s) : Imeglimin Hydrochloride
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Recipient : Metavant Sciences
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ombipepimut-S,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : DSP-7888 is an investigational immunotherapeutic cancer vaccine containing two peptides that induce WT1-specific cytotoxic T lymphocytes (WT1-CTL) and helper T cells to attack WT1-expressing cancerous cells found in various types of hematologic and solid...
Brand Name : DSP-7888
Molecule Type : Vaccine
Upfront Cash : Not Applicable
October 27, 2020
Lead Product(s) : Ombipepimut-S,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : TP-1454,Ipilimumab,Nivolumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The primary objectives of the first-in-human, open-label study are to assess the safety of oral TP-1454 administered once daily as monotherapy in patients with advanced metastatic or progressive solid tumors and as combination therapy with ipilimumab and...
Brand Name : TP-1454
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 09, 2020
Lead Product(s) : TP-1454,Ipilimumab,Nivolumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Dubermatinib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Preliminary findings from the Phase 1a/b first-in-human study indicated dubermatinib was well tolerated with a manageable safety profile as a monotherapy or in combination with immunotherapy or tyrosine kinase inhibitor (TKI).
Brand Name : TP-0903
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 18, 2020
Lead Product(s) : Dubermatinib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : These data, highlighting a novel biomarker detection method for CDK9 inhibition and evaluating the anti-tumor activity of alvocidib and TP-1287 in hematologic cancer cells, are being presented at the American Association for Cancer Research (AACR) Virtua...
Brand Name : TP-1287
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 22, 2020
Lead Product(s) : Alvocidib,Cytarabine
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Updated findings from the Phase 1, dose-escalation, safety and biomarker study of alvocidib followed by cytarabine and daunorubicin (7+3) induction therapy showed encouraging clinical activity and a tolerable safety profile in adults with newly diagnosed...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 12, 2020
Lead Product(s) : Alvocidib,Cytarabine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Preliminary findings from a Phase 1, first-in-human, dose escalation study of TP-1287 showed clinical activity and a tolerable safety profile as a monotherapy in patients with heavily pretreated, relapsed and refractory solid tumors.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 29, 2020
Details : Tolero intends to conduct a Phase 1/1b, first-in-human, open-label, dose‑escalation, safety, pharmacokinetic and pharmacodynamic study, which will evaluate oral TP‑1454 alone, and in combination with ipilimumab and nivolumab, in advanced metastatic o...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 19, 2020
LOOKING FOR A SUPPLIER?